Noble Financial Issues Negative Forecast for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Stock analysts at Noble Financial decreased their Q1 2027 earnings per share (EPS) estimates for Unicycive Therapeutics in a research note issued on Thursday, October 22nd. Noble Financial analyst R. Leboyer now expects that the company will earn ($0.14) per share for the quarter, down from their prior forecast of $0.64. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.16) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q2 2027 earnings at $0.49 EPS, Q3 2027 earnings at $0.67 EPS, Q4 2027 earnings at $0.79 EPS and FY2027 earnings at $1.81 EPS.

UNCY has been the subject of several other reports. Zacks Research raised shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 19th. Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. B. Riley Financial reaffirmed a “buy” rating and set a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. Finally, Benchmark reiterated a “speculative buy” rating and issued a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 20th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $18.25.

Unicycive Therapeutics Stock Performance

UNCY opened at $3.58 on Monday. The firm’s 50-day simple moving average is $4.68 and its 200-day simple moving average is $6.13. Unicycive Therapeutics has a twelve month low of $3.35 and a twelve month high of $8.74. The firm has a market cap of $99.70 million, a price-to-earnings ratio of -2.05 and a beta of 1.83.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.41.

Institutional Trading of Unicycive Therapeutics

Several large investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP raised its holdings in shares of Unicycive Therapeutics by 85.6% in the second quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock valued at $521,000 after buying an additional 47,700 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Unicycive Therapeutics during the 2nd quarter worth about $248,000. Bank of America Corp DE lifted its position in Unicycive Therapeutics by 19,327.6% during the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock worth $194,000 after buying an additional 29,378 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Unicycive Therapeutics during the 1st quarter worth about $161,000. Finally, Dimensional Fund Advisors LP bought a new stake in Unicycive Therapeutics during the 1st quarter worth about $940,000. Institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics News Summary

Here are the key news stories impacting Unicycive Therapeutics this week:

• Neutral Sentiment: Reported short interest was listed at 0 shares as of October 26, implying no measurable short-position overhang based on the provided data. However, the entry describes this as a large increase, so the figures may be inconsistent.
• Negative Sentiment: Multiple law firms reminded investors of a November 2 deadline to seek lead-plaintiff status in a securities class action covering purchases from December 29, 2025, through June 29, 2026. The repeated alerts increase attention around potential litigation costs, liability, and reputational risk. Glancy Prongay Wolke & Rotter deadline alert
• Negative Sentiment: The allegations center on statements that Unicycive reported its third-party manufacturer had made “significant progress” toward regaining FDA compliance without independently verifying that progress through an inspection. If substantiated, the claims could undermine confidence in the company’s regulatory and manufacturing disclosures. Levi & Korsinsky class-action alert
• Negative Sentiment: Noble Financial brokers reportedly reduced their earnings estimates for Unicycive, adding to concerns about the company’s outlook and reinforcing the stock’s speculative profile.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease and related metabolic complications. The company’s primary focus is hyperphosphatemia, an excess of phosphate in the blood that commonly affects people with chronic kidney disease, particularly those receiving dialysis.

Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an investigational, orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.